Skip to main content
. 2016 Apr 30;99:259–271. doi: 10.1007/s00223-016-0143-5

Table 1.

Baseline characteristics of patients in the ExFOS active treatment cohort

Characteristic Active treatment cohort (N = 1454)
Gender (females, males), n (%) 1318 (90.6), 136 (9.4)
Age (years), mean (SD) 70.2 (9.8)
Body mass index (kg/m2), mean (SD) 25.6 (4.5)
Patients with previous fracture, n (%) 1239 (85.2)
Number of previous fractures, median (Q1, Q3) 2.0 (1.0, 3.0)
Number of previous vertebral fractures, median (Q1, Q3) 2.0 (1.0, 3.0)
Patients with fractures in the 12 months before starting teriparatide, n (%) 688 (47.3)
Patients with vertebral fractures in the 12 months before starting teriparatide, n (%) 465 (32.0)
Patients with maternal history of hip fracture, n (%) 236 (19.5)
Uses arms when standing from chair, n (%) 756 (52.3)
Sight problems, n (%) 469 (32.5)
Current smoker, n (%) 214 (14.9)
Exercises ≥1 h/week, n (%) 861 (60.1)
Hours of exercise/weeka, median (Q1, Q3) 4.0 (2.0, 7.0)
Has at least one alcoholic drink/week, n (%) 507 (35.7)
Number of patients with falls in previous year, n (%)
 1 fall 287 (20.5)
 >1 fall 256 (18.2)
Immobilised for >12 months, n (%) 45 (3.1)
Reproductive history for females (n = 1318)b
 Reached menopause, n (%) 986 (98.5)
 Years since onset of menopause, median (Q1, Q3) 23.0 (16.0, 29.0)
 Early menopause (<40 years of age), n (%) 70 (5.8)
 Surgical menopause, n (%) 137 (10.9)
 Nulliparous, n (%) 147 (11.2)
Prior osteoporosis medication, n (%) 1289 (88.7)
Prior bisphosphonate use, n (%) 941 (64.7)
Duration of prior bisphosphonate therapy (months), mean (SD) 20.5 (36.6)
Current comorbidities, any disease, n (%) 487 (33.5)
Rheumatoid arthritis or other rheumatological disorder, n (%) 163 (11.2)
Taking glucocorticoids, n (%) 210 (14.4)

Percentages are based on patients with non-missing data

SD standard deviation, Q1, Q3 first and third quartile of interquartile range

aFor patients who reported exercising

bFifteen women were premenopausal